|Study Period:||2018 - 2026|
|Fastest Growing Market:||Asia Pacific|
|Largest Market:||North America|
Need a report that reflects how COVID-19 has impacted this market and its growth?
The benzodiazepine drugs market studied was anticipated to grow with a CAGR of 2.4%, during the forecast period. Benzodiazepines are a class of psychoactive drugs that are used to treat diseases like anxiety, insomnia, panic disorder, seizures, and alcohol withdrawal. Benzodiazepine drugs produce a calming effect by enhancing the effect of the neurotransmitter GABA (Gamma-Aminobutyric Acid). Benzodiazepines drugs are widely prescribed drugs across the world and are helpful to reduce anxiety disorders, seizures, inducing sleep and also used for sedation purposes prior to surgery or general anesthesia. Rise in the geriatric population, stressful lifestyle, daily habits are major factors for mental disturbance, which creates anxiety, maniac, and panic disorder conditions. The market for benzodiazepine drugs is expanding rapidly due to an increase in the prevalence of anxiety, seizures, insomnia, and a rise in concern for the prevention of stress and related conditions. Alprazolam segment is anticipated to expand growth due to its wide application in anxiety, panic disorders. However, misuse of benzodiazepine drugs may restrict the growth of this market.
Scope of the Report
Benzodiazepines is a class of psychoactive drugs that are used to treat diseases like anxiety, insomnia, panic disorder, seizures, and alcohol withdrawal. Benzodiazepine drugs are segmented by Products, Application, Time of Action and Geography.
|By Time of Action|
Key Market Trends
Anxiety Disorders Segment is Expected to Hold a Largest Market Share in the Benzodiazepine Drugs
Anxiety segment is anticipated to account for major share of the market during the forecast period.According to World Health Organization (WHO) estimated number of people living with anxiety disorders globally is 264 million in the year 2015 reflects a 14.9% increase since 2005, as a result of population growth and ageing and which is estimated to be 3.6%. Anxiety disorders are more common among females than males (4.6% in females compared to 2.6% in males at the global level).
In 2017, anxiety segment recorded more than 60% revenue share collectively with anti-depressants drugs and the boost in demand for anxiety therapeutics coupled with a rise in a number of companies investing to develop new anxiety drugs which drives the market revenue. Anxiety was a dominant segment of the benzodiazepines drug market globally in the year 2017 and expected to maintain same during the forecast period.
To understand key trends, Download Sample Report
North America is Expected to Dominate the Market and Expected to do Same in the Forecast Period
North America is expected to hold a dominating position in the global benzodiazepine drugs market due to more FDA approvals in that region. Around 40 million adults in the United States are affected every year with anxiety disorders of which only 36.9% receive treatment according to Anxiety and Depression Association of America (ADAA). Increase in the development of mental health-care services and rising awareness towards anxiety disorders are responsible for the increase in the diagnosis of generalized anxiety disorder (GAD). Due to growth in geriatric population is increasing the anxiety diagnosis rates in Mexico, thus directly boosting the demand for physiotherapies such as Cognitive Behavior Therapy (CBT) and generalized anxiety disorder (GAD) medication.
To understand geography trends, Download Sample Report
The Benzodiazepine Drugs Market is moderately competitive and consists of several players. In terms of market share, more number of the players are currently dominating the market. Some of the companies which are currently dominating the market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Bausch Health Companies, Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., H.Lundbeck A/S, Amneal Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd., Apotex Inc., and Aurobindo Pharma among others.
In September 2020, in Japan, Taisho Pharmaceutical Co., Ltd., initiated a phase II clinical trial to assess the efficacy of TS-142 in the treatment of insomnia. The trial is expected to complete in December 2021.
In February 2020, United States Food and Drug Administration provided approval to Merck for its Belsomra drug in the treatment of insomnia in patients with mild-to-moderate Alzheimer’s disease.
Table of Contents
1.1 Study Assumptions
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in Prevalence of Anxiety disorders, Seizures and Insomnia Diseases
4.2.2 Rise in Adoption of Generic Drugs
4.3 Market Restraints
4.3.1 Misuse of Benzodiazepine Drugs
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Product
5.2 By Application
5.2.1 Anxiety disorders
5.2.4 Alcohol Withdrawal
5.3 By Time of Action
5.3.1 Ultra-short Acting
5.3.2 Short Acting
5.3.3 Long Acting
5.4.1 North America
188.8.131.52 United States
184.108.40.206 United Kingdom
220.127.116.11 Rest of Europe
18.104.22.168 South Korea
22.214.171.124 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
126.96.36.199 South Africa
188.8.131.52 Rest of Middle-East and Africa
5.4.5 South America
184.108.40.206 Rest of South America
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.1 Amneal Pharmaceuticals LLC
6.1.2 Apotex Inc.
6.1.3 Aurobindo Pharma
6.1.4 Bausch Health Companies, Inc.
6.1.5 F.Hoffmann-La Roche Ltd.
6.1.6 H.Lundbeck A/S
6.1.7 Mylan, N.V.
6.1.8 Pfizer Inc.
6.1.9 Sun Pharmaceutical Industries Ltd.
6.1.10 Teva Pharmaceutical Industries Ltd.
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Benzodiazepine Drugs Market market is studied from 2018 - 2026.
What is the growth rate of Benzodiazepine Drugs Market?
The Benzodiazepine Drugs Market is growing at a CAGR of 2.4% over the next 5 years.
Which region has highest growth rate in Benzodiazepine Drugs Market?
Asia Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Benzodiazepine Drugs Market?
North America holds highest share in 2020.
Who are the key players in Benzodiazepine Drugs Market?
Pfizer Inc., F. Hoffmann-La Roche Ltd, Bausch Health Companies, Inc, Mylan N.V., Teva Pharmaceutical Industries Ltd are the major companies operating in Benzodiazepine Drugs Market.